Abstract library

99 results for "111In-pentetreotide scintigraphy".
#35 Primary Hyperparathyroidism in patients with gastric carcinoid Tumors type-1: an unusual coexistence
Introduction: Although a number of familiar endocrine syndromes are associated with primary hyperparathyroidism (PHP), there is no information regarding its prevalence in other sporadic neuroendocrine diseases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dimitrios Thomas
#760 Intraoperative Gamma Probe Detection of Metastatic Medullary Thyroid Carcinoma (MTC) with 111In-Pentetreotide
Introduction: MTC is a rare thyroid malignancy representing approximately 5-10% of all thyroid tumors. Early diagnosis and radical surgery are essential to reduce the morbidity and mortality associated with MTC. Somatostatin receptors (SSTRs) expression has been described in MTC with a variable pattern, SSTR2 being prevalent. Although somatostatin analogues demonstrated poor efficacy in the control of MTC growth, SSTR expression can be useful in Nuclear Medicine diagnostic procedures. 111In-pentetreotide scintigraphy and 68Ga-somatostatin analogues PET-CT represent valuable techniques in the detection of MTC, although with a lower sensitivity compared to 18F-DOPA PET-CT.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Laura De Marinis
Keywords: mtc, srs
#1300 Staging of Neuroendocrine Tumors: Value of Hybrid Imaging With 111In- Pentetreotide
Introduction: Neuroendocrine tumors (NET) are rare and can occur anywhere in the body. Ninety-eight percent of these tumors express the type 2 of somatostatin receptors, making possible the functional imaging of NET. 111In-labelled pentetreotide specifically binds to somatostatin receptors, with particular affinity to subtypes 2 and 5.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#1317 Value of Octreoscan and 18FDG-PET for Clinical Prognosis of Patients with Neuroendocrine Neoplasms
Introduction: Despite the existence of biological markers of aggressiveness, the clinical course of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN) remains difficult to predict. Discrepancies between imaging data generated with 111In-pentetreotide scintigraphy (SRS) and 18 F-FDG-PET could reflect the degree of cellular de-differentiation.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Francois Pralong
Authors: Gouffon M, Prior J, Ratib O, Krause T, ...
#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors
Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez
#2710 Ultrasonography Detects Most pNET
Introduction: Early detection of pancreatic neuroendocrine tumors (pNET) is problematic. Abdominal ultrasonography (US) applies to >10% of the german population each year, but many hesitations exist: observer dependency, lack of reliability, unvisible organ due to overlying gas
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. med. Matthias Lang
Authors: Lang M, Hackert T, Tjaden C, ...
#2825 Interest of PET-MRI in the Management of GIT NETs
Introduction: Assessment of GIT NET requires different imaging exams including CT, MRI, Scintigraphy. The hybrid PET-CT machine impacted the management of TNEs. The whole body PET-MRI version is available but poorly evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Prof. Iradj Sobhani
Keywords: PET, MRI, GIT-NET
#2839 The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan
Introduction: Japanese Neuroendocrine Tumor Society (JNETS) has published the first edition of clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in 2015. Then, according to an update on the diagnosis and management of GEP-NEN in Japan. Revised clinical practice guidelines, the second edition, has just published in 2019.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Tetsuhide Ito
Authors: Ito T, Masui T, Komoto I, ...
Keywords: GEP-NEN, Guideline, Japan
#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#2916 Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?
Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr. med. Christoph Wetz
Authors: Wetz C, Genseke P, Schatka I, Jann H, ...